Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 16/20 | 0.61 |
| ▸ | CRBN | Q96SW2 | 16/20 | 0.61 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30830715 | 0.92 | DDB1 (0.58) | DDB1CRBNGPR119USP30 | |
| SCHEMBL30965512 | 0.92 | DDB1 (0.58) | DDB1CRBNGPR119USP30 | |
| SCHEMBL31487408 | 0.92 | DDB1 (0.58) | DDB1CRBNGPR119USP30 | |
| SCHEMBL21876868 | 0.88 | DDB1 (0.63) | DDB1CRBNGPR119 | |
| SCHEMBL24880592 | 0.88 | CRBN (0.62) | DDB1CRBNGPR119 | |
| SCHEMBL30768973 | 0.87 | DDB1 (0.59) | DDB1CRBNGPR119USP30 | |
| SCHEMBL31607945 | 0.84 | DDB1 (0.58) | DDB1CRBNGPR119USP30 | |
| SCHEMBL31585478 | 0.82 | DDB1 (0.52) | DDB1CRBNGPR119 | |
| SCHEMBL31342602 | 0.81 | DDB1 (0.54) | DDB1CRBNGPR119USP30 | |
| SCHEMBL30981278 | 0.81 | DDB1 (0.54) | DDB1CRBNGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581025-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Auron Therapeutics, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024050078-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AURON THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |